Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3058% above fair value
$249.59+2.46 (+1.00%)
Close on Nov 20, 2026Market cap $36.89BP/E 106.7Yield –
Biogen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Biogen's operating income for the twelve months ending Mar 31, 2022 was $2.48B, down 33.1% year over year. For fiscal 2021 it was $2.84B, down 37.6% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $7.04B in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.84B | -37.6% |
| FY2020 | Dec 31, 2020 | $4.55B | -35.4% |
| FY2019 | Dec 31, 2019 | $7.04B | +19.6% |
| FY2018 | Dec 31, 2018 | $5.89B | +10.2% |
| FY2017 | Dec 31, 2017 | $5.35B | +3.8% |
| FY2016 | Dec 31, 2016 | $5.15B | +5.3% |
| FY2015 | Dec 31, 2015 | $4.89B | +23.1% |
| FY2014 | Dec 31, 2014 | $3.97B | +57.9% |
| FY2013 | Dec 31, 2013 | $2.52B | +35.5% |
| FY2012 | Dec 31, 2012 | $1.86B | +7.6% |
| FY2011 | Dec 31, 2011 | $1.72B | +38.1% |
| FY2010 | Dec 31, 2010 | $1.25B | -3.6% |
| FY2009 | Dec 31, 2009 | $1.30B | +6.7% |
| FY2008 | Dec 31, 2008 | $1.21B | +55.6% |
| FY2007 | Dec 31, 2007 | $779.77M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | $610.70M | -37.3% |
| Q4 FY2021 | Dec 31, 2021 | $587.10M | – |
| Q3 FY2021 | Sep 30, 2021 | $794.00M | -26.9% |
| Q2 FY2021 | Jun 30, 2021 | $485.70M | -75.4% |
| Q1 FY2021 | Mar 31, 2021 | $973.90M | -46.5% |
| Q4 FY2020 | Dec 31, 2020 | -$330.60M | -118.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.09B | -39.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.97B | +1.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.82B | +21.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.78B | +23.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.81B | +6.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.96B | +61.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.50B | -2.1% |
| Q4 FY2018 | Dec 31, 2018 | $1.44B | -1.6% |
| Q3 FY2018 | Sep 30, 2018 | $1.70B | +2.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.21B | +1.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.53B | +49.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.47B | +65.2% |
| Q3 FY2017 | Sep 30, 2017 | $1.65B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.20B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.02B | – |
| Q4 FY2016 | Dec 31, 2016 | $887.50M | – |
See a number that looks wrong?